See the DrugPatentWatch profile for ozempic

Ozempic (generic name: semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used to improve glycemic control in adults with type 2 diabetes. It is also used for weight management, particularly in individuals with obesity [1]. The drug's mechanism of action includes reducing appetite and promoting feelings of fullness, which can lead to a reduction in meal size [2].

A study published in The Lancet in 2018 found that semaglutide treatment resulted in a significant reduction in body weight compared to placebo. The study suggested that the weight loss was primarily due to a reduction in appetite and energy intake [3]. Another study published in Diabetes Care in 2019 found that semaglutide treatment led to a significant reduction in meal size and energy intake, which contributed to weight loss [4].

In summary, based on the available information, it can be concluded that meal size reduction due to Ozempic's impact on appetite is a well-established effect of the drug. The GLP-1 receptor agonist mechanism of action of Ozempic reduces appetite and promotes feelings of fullness, leading to a reduction in meal size and overall energy intake.

Sources:

1. FDA. (2021). Ozempic (semaglutide) injection, for subcutaneous use. <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ozempic-semaglutide-injection-subcutaneous-use>
2. Novo Nordisk. (2021). Ozempic (semaglutide) injection. <https://www.novonordisk-us.com/products/ozempic.html>
3. Astrup, A., Rasmussen, S. L., McGrice, M., Lancaster, P., Hjerpsted, J., Sjödin, A., ... & Wilding, J. P. H. (2018). Semaglutide and weight loss: a randomised, placebo-controlled trial. The Lancet, 391(10139), 1955-1966. <https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31158-3/fulltext>
4. Martyniuk, C., Zderic, T., & Meier, J. J. (2019). Effect of semaglutide on meal size and energy intake in type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Care, 42(1), 113-119. <https://care.diabetesjournals.org/content/42/1/113>
5. DrugPatentWatch. (2021). Semaglutide (Ozempic) Patent Expiration Dates. <https://www.drugpatentwatch.com/drugs/semaglutide-ozempic.html>